Related references
Note: Only part of the references are listed.Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place
A. Meerveld-Eggink et al.
ANNALS OF ONCOLOGY (2020)
Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma
Mary E. Westerman et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Eliana M. C. Tacconi et al.
ONCOTARGETS AND THERAPY (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
I Stukalin et al.
CURRENT ONCOLOGY (2019)
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
Axel Bex et al.
FUTURE ONCOLOGY (2019)
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D. Patel et al.
FUTURE ONCOLOGY (2019)
907PDADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma
L Au et al.
ANNALS OF ONCOLOGY (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study
Cedric Lebacle et al.
BJU INTERNATIONAL (2019)
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial
Axel Bex et al.
JAMA ONCOLOGY (2019)
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
A. Mejean et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
Axel Bex et al.
EUROPEAN UROLOGY (2018)
The Immunobiology of Kidney Cancer
Charles G. Drake et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
Axel Bex et al.
EUROPEAN UROLOGY (2017)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma
Aurelie Guislain et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Jose A. Karam et al.
EUROPEAN UROLOGY (2014)
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Maxine Sun et al.
EUROPEAN UROLOGY (2011)
Share Paper
